0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > TGF-beta 1

TGF-beta 1

Brief Information

Name:Transforming growth factor beta 1
Target Synonym:Latency-Associated Peptide,IBDIMDE,Transforming Growth Factor beta1,Prepro-Transforming Growth Factor Beta-1,TGF-Beta-1,Transforming Growth Factor, Beta 1,CED,TGFB,DPD1,TGFB1,Transforming Growth Factor Beta-1 Proprotein,Camurati-Engelmann Disease,LAP,TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-TG1H25-Cell-based assay
 TGF-beta 1 CELL

GMP Human TGF-Beta 1 Protein (Cat. No. GMP-TG1H25) inhibits the GMP Human IL-4 Protein (Cat. No. GMP-L04H26) dependent proliferation the TF-1 cells. The specific activity of GMP Human TGF-Beta 1 Protein is > 6.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code:89/514) (QC tested).

TG1-H5218-Cell-based assay
 TGF-beta 1 CELL

Human TGF-beta 1, premium grade (Cat. No. TG1-H5218) inhibits the Human IL-4, premium grade (Cat. No. IL4-H4218) dependent proliferation the TF-1 cells. The specific activity of Human TGF-beta 1, premium grade is > 6.00ⅹ10^6 IU/mg, which is calibrated against transforming growth factor β1 (NIBSC code:89/514) (QC tested).

TG1-H4212-SPR
 TGF-beta 1 SPR

Human TGF-Beta 1 Protein, Tag Free (Cat. No. TG1-H4212) immobilized on CM5 Chip can bind Human TGF-beta RI Protein, Fc Tag (Cat. No. TG1-H5254) with an affinity constant of 99.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

TG1-M5218-ELISA
 TGF-beta 1 ELISA

Immobilized Mouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) at 0.2 μg/mL (100 μL/well) can bind Biotinylated Mouse TGF-beta RII, His,Avitag (Cat. No. TG2-M82H5) with a linear range of 1-20 ng/mL (QC tested).

Customer Reviews

Synonym Name

CEDLAP,TGF-beta 1,TGFB1,DPD1,TGF-beta-1,TGFB

Background

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vactosertib TEW-7197; EW-7197; NOV-1301 Phase 3 Clinical Medpacto Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Esophageal adenocarcinoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms Details
Nisevokitug NIS-793 Phase 3 Clinical Xoma Corp Kidney Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma Details
SB-01 (Spine Biopharma) SB-01 Phase 3 Clinical Spine BioPharma Inc Intervertebral disc disease; Low Back Pain Details
Dalutrafusp alfa GS-1423; AGEN-1423 Phase 2 Clinical Agenus Inc Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal Details
ZSP-1603 ZSP-1603 Phase 2 Clinical Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
Meflonidone hydrochloride Phase 2 Clinical Guangzhou Nanxin Pharma Co Ltd, Central South University Diabetes Mellitus, Type 2; Diabetic Nephropathies Details
Fluorofenidone AKF-PD Phase 2 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis Details
Cotsiranib STP-705LU; STP-705LV; STP-705; STP-705L Phase 2 Clinical Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Liver Neoplasms; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Cholangiocarcinoma; Obesity, Abdominal; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial Details
YL-13027 YL-13027 Phase 2 Clinical YL-Pharma Solid tumours; Pancreatic Neoplasms Details
Linavonkibart SRK-181 Phase 1 Clinical Scholar Rock Neoplasms Details
Charis-1000 Charis-1000; C 1K; C1K Phase 1 Clinical Breast Neoplasms Details
HLX-6018 HLX-6018; HLX6018 Phase 1 Clinical Shanghai Henlius Biotech Inc Idiopathic Pulmonary Fibrosis Details
JYB-1907 JYB-1907 Phase 1 Clinical Jiangxi Jemincare Group Co Ltd Solid tumours Details
STP-707 STP-707 Phase 1 Clinical Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Solid tumours; Liver Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing Details
PXS-64 PXS-64 Phase 1 Clinical Multiple Sclerosis Details
Livmoniplimab MGH-8; ARGX-115; AGRX-115; ABBV151 Phase 1 Clinical Argenx Se Carcinoma, Hepatocellular Details
AVID-200 AVID-200; BMS-986416; AVID-200 DP Phase 1 Clinical Formation Biologics Corp Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

totop

Laisser un message